drugset / Trial / NCT00512291
Subcutaneous Olanzapine for Hyperactive or Mixed Delirium
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objective of this study is to determine the tolerability and safety of olanzapine administered as a subcutaneous injection to hospitalized patients with hyperactive or mixed delirium.
Timeline
- Start
- 2005-06
- Primary completion
- 2007-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olanzapine | Small molecule | 5 mg | Subcutaneous |